DrugDashboards

Rifampin

Rifampin · RIFAMPIN 600 mg/1 · Injection, Powder, Lyophilized, For Solution · Intravenous · Hikma Pharmaceuticals USA Inc.

NDC 00143-9230-01 · 1 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION in 1 VIAL · ANDA · View full market →

The short version

4 companies supply this market — a reasonable cushion if one runs into trouble. It is in shortage right now — FDA lists the reason as “discontinuation of the manufacture of the drug”.

The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.

Medicare Part D

No Medicare Part D plan in CMS's quarterly files lists this product. That usually means it is discontinued, a repackager's listing, or a product no plan has added to its formulary.

How Part D pricing works →

NADAC price per unit

No NADAC pricing on file for this NDC — NADAC covers drugs dispensed by retail community pharmacies.

Supply fragility

Not scored — fragility is computed for NADAC-priced NDCs.

Where it's made

Establishments this product's FDA label declares, located via FDA registration data. How we built this →

Is this a "specialty" drug?

There's no legal definition — it meets 1 of 6 public criteria. Why that matters →

  • Part D specialty tier
  • Costs ≥ $950/fill · avg $61.54 per prescription
  • Biologic (BLA)
  • Injectable / infused
  • Orphan-drug exclusivity
  • REMS program

Regulatory

Application
ANDA205039
TE code
AP
Approval date
Mar 3, 2016
Patents / exclusivity
None on file

Shortage history

  • In shortage now — Rifadin, Injection, 600 mg (NDC 0068-0597-01)Feb 17, 2021
    Discontinuation of the manufacture of the drug
    month 67 — 3× the typical 20-month injectable shortage · model puts 14% odds it resolves within 6 months
  • Planned discontinuation — Rifadin, Injection, 600 mg/10 mL (NDC 0068-0597-01)Feb 17, 2021
  • In shortage now — Rifampin, Injection, 600 mg (NDC 63323-351-20)Feb 17, 2021
    month 67 — 3× the typical 20-month injectable shortage · model puts 14% odds it resolves within 6 months
  • In shortage now — Rifampin, Injection, 600 mg (NDC 67457-445-60)Feb 17, 2021
    Demand increase for the drug
    month 67 — 3× the typical 20-month injectable shortage · model puts 14% odds it resolves within 6 months
  • In shortage now — Rifampin, Injection, 600 mg/10 mL (NDC 67457-445-60)Feb 17, 2021
    Demand increase for the drug
    month 67 — 3× the typical 20-month injectable shortage · model puts 14% odds it resolves within 6 months

Recalls (this NDC)

No enforcement reports list this package NDC.

Manufacturers of Rifampin (Injection, Powder, Lyophilized, For Solution)

LabelerStrengthFirst seenLast seen
Fresenius Kabi USA, LLCRIFAMPIN 600 mg/1Jul 15, 2026Sep 2, 2026
Hikma Pharmaceuticals USA Inc.RIFAMPIN 600 mg/1Jul 15, 2026Sep 2, 2026
Mylan Institutional LLCRIFAMPIN 600 mg/10mLJul 15, 2026Sep 2, 2026
Sanofi-Aventis U.S. LLCRIFAMPIN 600 mg/10mLJul 15, 2026Sep 2, 2026

Roster from daily NDC Directory diffs — first/last seen dates start July 2026.

Cite this page

DrugDashboards, "Rifampin — NDC 00143-9230-01," retrieved September 3, 2026, https://drugdashboards.com/drug/00143923001.

Free to cite with attribution — see how the data is put together.